Dosing | Lexette® Foam (halobetasol propionate)

The recommended dose is 50 grams per week for up to 2 weeks¹

The average patient had 5.4% BSA affected and used 5.1 grams of LEXETTE Foam per day
Treatment beyond 2 weeks is not recommended and the total dosage should not exceed 50 grams per week
Discontinue therapy when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary
LEXETTE Foam is for skin use only. Do not get LEXETTE Foam in the mouth, eyes, or vagina

Easy step-by-step instructions to share with patients¹

Before applying LEXETTE Foam for the first time, remove cap and break the small tab at the base of the actuator by gently pushing the actuator away from the tab. Do not break the hinge on the actuator.
Shake the can well before use.
Turn the can completely upside down.
Press down on the actuator to dispense a small amount of foam into the palm of your hands.
Apply a thin layer of LEXETTE Foam to the affected skin area. Gently rub LEXETTE Foam into the affected skin until the foam disappears.
Repeat Steps 4 and 5 to all the affected areas as prescribed.
After applying LEXETTE Foam, put the cap back on the can.
Wash hands after applying LEXETTE Foam unless the medication is used to treat hands.

A man applying LEXETTE Foam to his elbow

How is LEXETTE Foam supplied?

LEXETTE Foam is available to patients as 50 grams or 100 grams (supplied as two 50-gram cans).

Take a closer look at the formulation of LEXETTE Foam

See what makes it different

Help patients save on their prescription

SEE SAVINGS OFFER

Take a look at another foam for plaque psoriasis from Mayne Pharma >

Indication

LEXETTE^® Foam (halobetasol propionate) is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 12 years and older.

Important Safety Information

LEXETTE^® Foam (halobetasol propionate) is a topical corticosteroid that has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis.

Systemic effects of topical corticosteroids may include reversible HPA axis suppression, with the potential for glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of treatment of the topical corticosteroid.

The potential for hypothalamic-pituitary adrenal (HPA) suppression with LEXETTE Foam was evaluated in a study of 25 adult subjects with moderate to severe plaque psoriasis involving ≥15% of their body surface area. LEXETTE Foam produced laboratory evidence of HPA axis suppression when used twice daily for two weeks in 6 out of 25 (24%) adult subjects with plaque psoriasis. Recovery of HPA axis function was generally prompt with the discontinuation of treatment.

Systemic effects of topical corticosteroids may also include Cushing's syndrome, hyperglycemia, and glucosuria. Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids.

Local adverse reactions from topical corticosteroids may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. These may be more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids, including LEXETTE Foam.

Some local adverse reactions may be irreversible. Use of topical corticosteroids may increase the risk of posterior subcapsular cataracts and glaucoma.

To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

How to use LEXETTE Foam

The recommended dose is 50 grams per week for up to 2 weeks1

Easy step-by-step instructions to share with patients1